Piper Sandler raised the firm’s price target on Rapt Therapeutics to $31 from $28 and keeps an Overweight rating on the shares post the Q2 report. The analyst rolled forward the stock’s discount period to mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAPT: